$AVBP News

ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $47

Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $40

Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target

BTIG Reiterates Buy on ArriVent BioPharma, Maintains $42 Price Target

ArriVent BioPharma Reports Second Quarter 2026 Financial Results

ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) Estimate

Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $43

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Biopharma Launches $250M At-The-Market Common Stock Offering Through Jefferies

ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate

A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

ArriVent BioPharma: A First Assessment

Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest